William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
PRNEWSWIRE
SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire/ -- Hyperion Therapeutics,
Inc., a privately-held biopharmaceutical company focused on the development
and commercialization of hepatology and gastrointestinal therapies that
address orphan and underserved patient populations with unmet medical needs,
today announced that William R. Ringo has been elected to its Board of
Directors and will serve as Chairman.
Mr. Ringo brings to the Hyperion Board thirty-five years of experience
working with public and private pharmaceutical and biotechnology companies. He
is the former President and Chief Executive Officer of Abgenix, Inc., which
sold for $2.7 billion to Amgen in April 2006. In 2001 he retired from Eli
Lilly & Company as Product Group President for Oncology and Critical Care.
During his twenty-eight years at Eli Lilly & Company, Mr. Ringo held a number
of senior positions including President of Internal Medicine Products,
President of Infectious Diseases Business Unit, and Vice President of Sales
and Marketing for U.S. Pharmaceuticals. He is currently an
Executive-in-Residence at Sofinnova Ventures and serves as Chairman of the
Board of Directors at Intermune and a member of the Board of Directors of
Inspire Pharmaceuticals, Allos Therapeutics, Alvine Pharmaceuticals, Portola
Pharmaceuticals, and BioCrossroads, a not for profit organization. Mr. Ringo
holds a B.S. and an M.B.A. from the University of Dayton.
"We are very excited to have Bill join Hyperion as our Chairman," said
Chris Rivera, President and CEO. "Having someone with his experience and track
record in the industry on our Board should help us continue to build value in
Hyperion, as well as execute our long-term strategy."
About Hyperion Therapeutics
Hyperion Therapeutics is a specialty therapeutics company focused on
becoming a global leader in hepatology and gastrointestinal (GI) therapeutic
programs and products that address orphan and underserved patient populations
with unmet medical needs. The company has assembled a seasoned executive team
with extensive industry experience developing and commercializing specialty
pharmaceutical products. Hyperion is headquartered in South San Francisco,
CA. For additional information, visit: http://www.hyperiontx.com.
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
News
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All